Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:57:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.11 CAD +4.46% Intraday chart for NervGen Pharma Corp. -5.38% -21.85%
Apr. 17 NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
Apr. 17 NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about NervGen Pharma Corp.

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NervGen Pharma Closes C$23 Million Bought Deal Financing MT
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units MT
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291 CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury CI
Nervgen Pharma Appoints John Ruffolo to Board of Directors CI
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury CI
NervGen Pharma Corp. Receives $3.18 Million Grant from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nervgen Pharma Corp. Appoints Michael Kelly as CEO CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
NervGen Pharma Reports Dosing of All Subjects in Phase 1 Clinical Trial of Drug Candidate NVG-291 MT
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291 CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 CI
NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury CI
NervGen Pharma Corp. Announces Executive Changes CI
NervGen Pharma Corp. Announces Executive Changes CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
NervGen Pharma Corp.(TSXV:NGEN) added to S&P/TSX Venture Composite Index CI

Chart NervGen Pharma Corp.

Chart NervGen Pharma Corp.
More charts

Company Profile

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.
Sector
Biotechnology & Medical Research
Calendar
2024-05-14 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.11 CAD
Average target price
5 CAD
Spread / Average Target
+136.97%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NERVGEN PHARMA CORP. Stock NervGen Pharma Corp.
-21.85% 103M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.7B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. News NervGen Pharma Corp.
  5. NervGen Pharma Up 3% after Reporting Completion of Non-Brokered Private Placement